Estradiol stimulates apolipoprotein A-I- but not A-II-containing particle synthesis and secretion by stimulating mRNA transcription rate in Hep G2 cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 6, 1998, Pages 999-1006

  Jin, Fu You ^b   Kamanna, Vaijinath S ^b   Kashyap, Moti L ^a  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

Apolipoprotein A I; Cardiovascular disease; Estrogen; High density lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ESTRADIOL; HIGH DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; ESTROGEN THERAPY; HEART PROTECTION; HUMAN; HUMAN CELL; LIPOPROTEIN METABOLISM; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0031798977     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.6.999     Document Type: Article

References (20)

1. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary artery disease. N Engl J Med. 1989;321:1311-1316.
2. Lyons Wall PM, Choudhary N, Gerbrandy EA, Truswell AS. Increase of HDL cholesterol at ovulation in healthy women. Atherosclerosis. 1994; 105:1171-1178.
3. Sacks FM, Walsh BW. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol. 1994;5:236-240.
4. Walsh BW, Schiff I, Rosner B, Breenberg L, Ravinkar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325: 1196-1204.
5. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial [published correction appears in JAMA. 1995;274:1676]. JAMA. 1995;273:199-208.
6. Lobb RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 1991;73:925-930.
7. Stampfer MJ, Colditz GA. Estrogen replacement and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
8. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
9. Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography: particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem. 1984;259: 12201-12209.
10. Parra HJ, Mezdour H, Ghalim N, Bard JM, Fruchart JC. Differential electroimmunoassay of human LP-A-I lipoprotein particles on ready-to-use plates. Clin Chem. 1990;36:1431-1435.
11. Brinton EA. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler Thromb Vasc Biol. 1996;16:431-440.
12. Warden CH, Kedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993;261:469-472.
13. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 1993;365:762-764.
14. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature. 1991;353:265-267.
15. Puchois P, Kandoussi A, Fievet P, Fourrier JL, Koren E, Fruchart JC. Apolipoprotein A-I-containing lipoproteins in coronary artery disease. Atherosclerosis. 1987;68:35-40.
16. Amouyel P, Isorez D, Bard J-M, Goldman M, Lebel P, Zylberberg G, Fruchart JC. Parental history of early myocardial infarction is associated with decreased levels of lipoparticle A-I in adolescents. Arterioscler Thromb. 1993;13:1640-1644.
17. Genest J Jr, Bard JM, Fruchart JC, Ordovas JM, Schaefer EJ. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler Thromb. 1993;13:1728-1737.
18. Sacks FM, Gerhard M, Walsh BW. Sex hormones, lipoproteins, and vascular reactivity. Curr Opin Lipidol. 1995;6:161-166.
19. Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer HB Jr, Levy RI. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab. 1983;57:262-267.
20. Walsh BW, Li II, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res. 1994;35:2083-2093.